SCN9A and prostate cancer: Rizaner et al. showed for strongly metastatic rat prostate cancer Mat-LyLu cells that ranolazine (i) inhibited Matrigel invasion under both normoxic and hypoxic conditions and (ii) reduced the percentage of cells in the lung metastases expressing Nav1.7 [35].